Viome is the lead sponsor of 10 current clinical trials in our USA and Brazil registers. 10 are recruiting patients now. The most common phase is Observational. The most-studied condition is Diabetes.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c
NCT06185192 · Diabetes
|
Not applicable | Recruiting | 2023-12 | USA |
|
Human and Microbial Determinants of the Onset of IBD Flares
NCT06967311 · ClinicalTrials.gov ↗ · IBD (Inflammatory Bowel Disease)
|
Observational | Recruiting | 2025-01 | Brazil |
|
Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c
NCT05465616 · ClinicalTrials.gov ↗ · Diabetes, Pre Diabetes
|
Not applicable | Recruiting | 2022-08 | USA |
|
Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy
NCT04957511 · ClinicalTrials.gov ↗ · Gynecologic Cancer, Immunotherapy, Gut Microbiome
|
Observational | Recruiting | 2021-06 | USA |
|
Viome Nutritional Programs to Improve Clinical Outcomes for Gastrointestinal Conditions
NCT05465629 · ClinicalTrials.gov ↗ · Gastrointestinal Health
|
Not applicable | Recruiting | 2022-11 | USA |
|
Collection and Analyses of Physiological, Physical, and Molecular Data From a Diverse Population
NCT06381232 · ClinicalTrials.gov ↗ · General Health, Wellness
|
Observational | Recruiting | 2018-07 | USA |
|
Metatranscriptomic Markers of Colonic Neoplasia
NCT07786818 · ClinicalTrials.gov ↗ · Colorectal Polyps
|
Observational | Recruiting | 2025-12 | USA |
|
Validity of Viome's Oral/throat Cancer Test
NCT06174428 · ClinicalTrials.gov ↗ · Oral and Throat Cancer, Oropharyngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma
|
Observational | Recruiting | 2025-01 | USA |
|
Detection of Oral and Throat Cancers Using OralViome Cancer Testing System
NCT05451303 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma, Premalignant Lesion
|
Observational | Recruiting | 2022-05 | USA |
|
Viome Nutritional Programs to Improve Clinical Outcomes for Metabolic Conditions
NCT05564273 · ClinicalTrials.gov ↗ · Metabolic Health
|
Not applicable | Recruiting | 2023-10 | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 9 | 9 |
| Clinical trials in Brazil | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Sponsors with the most current trials registered for this condition.
Viome is the lead sponsor of 10 current trials on ClinicalTrials.gov in our USA and Brazil registers, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 10 of its 10 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.